Building A 7%-Yielding Dividend Growth Portfolio With SCHD As Its Core HoldingSeeking Alpha • 10/29/26
Merck tops quarterly estimates, hikes profit outlook as new form of Keytruda shows strengthCNBC • 10/29/26
Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2026 Financial Results; Highlights Multiple Milestones Advancing Broad, Diverse PipelineBusiness Wire • 10/29/26
Brokers Suggest Investing in Merck (MRK): Read This Before Placing a BetZacks Investment Research • 10/28/26
4 Blue-Chip Dividend Stocks That Could Turn $200,000 Into Annual Retirement Income24/7 Wall Street • 10/27/26
Sacituzumab Tirumotecan (Sac-TMT) Reduced the Risk of Death by 32% and the Risk of Disease Progression or Death by 41% Compared to Chemotherapy in Certain Patients With Advanced or Recurrent Endometrial CancerBusiness Wire • 10/26/26
LLY vs. MRK: Which Stock Offers the More Compelling Investment Case?Zacks Investment Research • 10/26/26
Countdown to Merck (MRK) Q3 Earnings: A Look at Estimates Beyond Revenue and EPSZacks Investment Research • 10/26/26
Beyond Keytruda: The Critical Pipeline Metrics to Watch in Merck's Q3 Results on Oct. 2924/7 Wall Street • 10/25/26
Merck And Moderna Diverge On Cancer Vaccine Results. Do They Still Have A Viable Drug?Investors Business Daily • 10/23/26
Doctors call Moderna, Merck's cancer vaccine data a major advancement — even as stocks fallCNBC • 10/23/26